FCN-159 for NF2-associated nerve sheath tumors (Phase II)
An Open, Single-Arm Phase II Study Evaluating the Efficacy and Safety of FCN-159 in Selected NF2-associated Nerve Sheath Tumors
This trial tests whether the MEK inhibitor FCN-159 can shrink or control nerve sheath tumors in people aged 16 and older with NF2.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Drugs / interventions | Selumetinib, immunotherapy, Radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06553365 on ClinicalTrials.gov |
What this trial studies
This is a phase II, single-arm, single-center trial enrolling about 30 patients with NF2-associated nerve sheath tumors. Participants aged 16 and older with measurable lesions and adequate organ function will receive FCN-159, an oral MEK inhibitor. The primary endpoint is objective response rate (ORR), with secondary outcomes including clinical benefit rate (CBR), 24-week hearing/functional scores (WRS), and overall survival (OS). Safety and tolerability will be monitored throughout treatment.
Who should consider this trial
Good fit: Ideal candidates are people aged 16 or older with NF2-associated nerve sheath tumors that are measurable by REiNS/RECIST, who have KPS ≥70 and require systemic therapy or have unresectable/ recurrent disease.
Not a fit: Patients with poor performance status (KPS <70), inadequate organ or bone marrow function, no measurable lesion, or who cannot follow contraception/safety requirements are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, FCN-159 could shrink or slow growth of NF2-related nerve sheath tumors, reducing symptoms and delaying more invasive treatments.
How similar studies have performed: MEK inhibitors have shown benefit in related nerve sheath conditions such as NF1-associated plexiform neurofibromas, but evidence for MEK inhibition specifically in NF2-associated tumors is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. ≥16 years of age, regardless of gender.
2. meet the revised 2022 diagnostic criteria for NF2-associated nerve sheath tumors or pathologically confirmed NF2-associated nerve sheath tumors.
3. should meet one of the following criteria: 1) Incomplete surgical resection, or postoperative recurrence. 2) Systemic therapy is required as determined by the Investigator.
4. the presence of a measurable lesion, as defined by REiNS or RECIST V1.1 criteria.
5. Karnofsky physical status score of ≥70.
6. the patient has adequate organ and bone marrow function.
7. International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN.
8. For patients of childbearing potential: During treatment and for at least 90 days after the last dose, patients should agree to use a highly effective method of contraception.
9. avoid excessive sun exposure and be willing to use an adequate amount of sunscreen in anticipation of sun exposure.
10. be able to understand and voluntarily sign a written informed consent form.
Exclusion Criteria:
* Previously received one of the following treatments:
1. Pharmaceutical or biological therapy within 3 weeks or 5 half-lives prior to enrollment, whichever is longer.
2. Use of growth factors that promote platelet, red blood cell, or white blood cell count or function within 7 days prior to enrollment.
3. Patients who have received major surgery or anti-tumor immunotherapy within 4 weeks prior to enrollment.
4. Radiation therapy for nerve sheath tumors within 4 weeks prior to enrollment.
5. Dose adjustment for patients treated with dexamethasone or other corticosteroids within 1 week prior to enrollment.
6. Patients who have participated in another interventional clinical trial within 4 weeks prior to enrollment.
7. Prior treatment with Selumetinib or any other MEK 1/2 inhibitor. 2. history of or concurrent with other malignancies. 3. inability to undergo MRI and/or contraindications to MRI. 4. uncontrolled hypertension. 5. the presence of dysphagia, active gastrointestinal disease, malabsorption syndrome, or other condition that interferes with the absorption of the study medication.
6\. previous or current retinal vascular disease. 7. interstitial pneumonitis 8. cardiac function or co-morbidities 9. Immediate family history of sudden cardiac death before age 50. 10.History of any acute neurological condition 11. with active bacterial, fungal or viral infections 12. known hypersensitivity to the study drug, other MEK1/2 inhibitors, or their excipients.
Where this trial is running
Beijing, Beijing Municipality
- Shuhang Wang — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Ning Li, M.D.
- Email: yalejiang@cicams.ac.cn
- Phone: +86 135-5271-5820
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.